Literature DB >> 23797888

Complete clinical response after neoadjuvant chemoradiotherapy for squamous cell cancer of the thoracic oesophagus: is surgery always necessary?

Carlo Castoro1, Marco Scarpa, Matteo Cagol, Rita Alfieri, Alberto Ruol, Francesco Cavallin, Silvia Michieletto, Giampietro Zanchettin, Vanna Chiarion-Sileni, Luigi Corti, Ermanno Ancona.   

Abstract

BACKGROUND: Neoadjuvant chemoradiotherapy (CT-RT) before oesophagectomy is standard management for squamous cell carcinoma(SCC) of the thoracic oesophagus. The aim of this study was to compare the outcome of patients who had clinical complete response(CR) with neoadjuvant CT-RT + oesophagectomy with the survival of patients who had clinical CR and were not operated on. PATIENTS AND METHODS: Seventy-seven consecutive patients with SCC of the thoracic oesophagus with CR with neoadjuvant CT-RT presenting at the Regional Center of Esophageal Diseases from 1992 to 2008 were included in this retrospective study on a prospectively collected database. Thirty-nine patients underwent oesophagectomy (CT-RT + oesophagectomy), while 38(CT-RT) were not operated on because they were considered unfit for surgery or refused the operation. Patients’ outcome and survival were compared.
RESULTS: In the CT-RT + oesophagectomy group, clinical CR was confirmed after histological examination of the surgical specimen in 27/39 (69.2 %) patients. Five-year overall survival rates were 50.0 % in the CT-RT + oesophagectomy group and 57.0 % in the CT-RT group (p=0.99); 5-year disease-free survival rates were 55.5%in the CT-RT + oesophagectomy group and 34.6%in the CTRT group (p=0.15). Even after adjusting for propensity score, age, ASA and clinical stage, the treatment regimen did not show a statistically significant effect on overall survival (adjusted p=0.65) nor on disease-free survival (adjusted p=0.15).
CONCLUSION: In our group of patients with clinical CR after neoadjuvant CT-RT for SCC of the thoracic oesophagus, waiting for recurrence and then using salvage surgery did not negatively impact their survival compared to patients treated with surgery. More accurate restaging protocols are warranted to improve decision making after CR with neoadjuvant CT-RT.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23797888     DOI: 10.1007/s11605-013-2269-3

Source DB:  PubMed          Journal:  J Gastrointest Surg        ISSN: 1091-255X            Impact factor:   3.452


  36 in total

1.  New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada.

Authors:  P Therasse; S G Arbuck; E A Eisenhauer; J Wanders; R S Kaplan; L Rubinstein; J Verweij; M Van Glabbeke; A T van Oosterom; M C Christian; S G Gwyther
Journal:  J Natl Cancer Inst       Date:  2000-02-02       Impact factor: 13.506

2.  Is preoperative chemoradiation effective in treatment of oesophageal carcinoma?

Authors:  C Mariette; J-P Triboulet
Journal:  Lancet Oncol       Date:  2005-09       Impact factor: 41.316

3.  Risk factors for complications after esophageal cancer resection: a prospective population-based study in Sweden.

Authors:  Pernilla Viklund; Mats Lindblad; Ming Lu; Weimin Ye; Jan Johansson; Jesper Lagergren
Journal:  Ann Surg       Date:  2006-02       Impact factor: 12.969

4.  Endoscopic ultrasonography in the staging of esophageal carcinoma after preoperative radiotherapy and chemotherapy.

Authors:  E Laterza; G de Manzoni; A Guglielmi; L Rodella; P Tedesco; C Cordiano
Journal:  Ann Thorac Surg       Date:  1999-05       Impact factor: 4.330

5.  Pathologic T0N1 esophageal cancer after neoadjuvant therapy and surgery: an orphan status.

Authors:  Min P Kim; Arlene M Correa; Jared Lee; David C Rice; Jack A Roth; Reza J Mehran; Garrett L Walsh; Jaffer A Ajani; Dipen M Maru; Joe Y Chang; Edith M Marom; Homer A Macapinlac; Jeff H Lee; Ara A Vaporciyan; Thomas Rice; Stephen G Swisher; Wayne L Hofstetter
Journal:  Ann Thorac Surg       Date:  2010-09       Impact factor: 4.330

6.  Cancer statistics, 2005.

Authors:  Ahmedin Jemal; Taylor Murray; Elizabeth Ward; Alicia Samuels; Ram C Tiwari; Asma Ghafoor; Eric J Feuer; Michael J Thun
Journal:  CA Cancer J Clin       Date:  2005 Jan-Feb       Impact factor: 508.702

7.  Responders benefit from neoadjuvant radiochemotherapy in esophageal squamous cell carcinoma: results of a prospective phase-II trial.

Authors:  B L D M Brücher; H J Stein; F Zimmermann; M Werner; M Sarbia; R Busch; H J Dittler; M Molls; U Fink; J R Siewert
Journal:  Eur J Surg Oncol       Date:  2004-11       Impact factor: 4.424

Review 8.  Current status of neoadjuvant therapy for adenocarcinoma of the distal esophagus.

Authors:  Johannes Zacherl; Andreas Sendler; Hubert J Stein; Katja Ott; Marcus Feith; Raimund Jakesz; J Rüdiger Siewert; Ulrich Fink
Journal:  World J Surg       Date:  2003-08-28       Impact factor: 3.352

9.  Response evaluation by endoscopy, rebiopsy, and endoscopic ultrasound does not accurately predict histopathologic regression after neoadjuvant chemoradiation for esophageal cancer.

Authors:  Paul M Schneider; Ralf Metzger; Hartmut Schaefer; Frank Baumgarten; Daniel Vallbohmer; Jan Brabender; Eva Wolfgarten; Elfriede Bollschweiler; Stephan E Baldus; Hans P Dienes; Arnulf H Hoelscher
Journal:  Ann Surg       Date:  2008-12       Impact factor: 12.969

10.  Neoadjuvant chemoradiotherapy for locally advanced esophageal cancer: experience at a single institution.

Authors:  S Christopher Malaisrie; Brian Untch; Gerard V Aranha; Najeeb Mohideen; Alexander Hantel; Jack Pickleman
Journal:  Arch Surg       Date:  2004-05
View more
  24 in total

Review 1.  The evolution of cancer surgery and future perspectives.

Authors:  Lynda Wyld; Riccardo A Audisio; Graeme J Poston
Journal:  Nat Rev Clin Oncol       Date:  2014-11-11       Impact factor: 66.675

2.  Optimal Therapy in Locally Advanced Esophageal Cancer: a National Cancer Database Analysis.

Authors:  William M Whited; Jaimin R Trivedi; Emily R Bond; Victor H van Berkel; Matthew P Fox
Journal:  J Gastrointest Surg       Date:  2017-09-22       Impact factor: 3.452

3.  Non responders to neoadjuvant chemoradiation for esophageal cancer: why better prediction is necessary.

Authors:  Chantal M den Bakker; Justin K Smit; Anna M E Bruynzeel; Nicole C T van Grieken; Freek Daams; Sarah Derks; Miguel A Cuesta; John T M Plukker; Donald L van der Peet
Journal:  J Thorac Dis       Date:  2017-07       Impact factor: 2.895

Review 4.  Update on Management of Squamous Cell Esophageal Cancer.

Authors:  John K Waters; Scott I Reznik
Journal:  Curr Oncol Rep       Date:  2022-02-10       Impact factor: 5.075

5.  Oncological outcomes of squamous cell carcinoma of the cervical esophagus treated with definitive (chemo-)radiotherapy: a systematic review and meta-analysis.

Authors:  Armando De Virgilio; Andrea Costantino; Carlo Castoro; Giuseppe Spriano; Bianca Maria Festa; Giuseppe Mercante; Davide Franceschini; Ciro Franzese; Marta Scorsetti; Andrea Marrari; Raffaele Cavina; Salvatore Marano
Journal:  J Cancer Res Clin Oncol       Date:  2022-03-02       Impact factor: 4.553

6.  PET Imaging and Rate of Pathologic Complete Response in Esophageal Squamous Cell Carcinoma.

Authors:  M Hart Squires; Nicole Gower; Jennifer H Benbow; Erin E Donahue; Casey E Bohl; Roshan S Prabhu; Joshua S Hill; Jonathan C Salo
Journal:  Ann Surg Oncol       Date:  2021-10-09       Impact factor: 5.344

Review 7.  Esophageal cancer: staging system and guidelines for staging and treatment.

Authors:  Mark F Berry
Journal:  J Thorac Dis       Date:  2014-05       Impact factor: 2.895

8.  Added value of MRI to endoscopic and endosonographic response assessment after neoadjuvant chemoradiotherapy in oesophageal cancer.

Authors:  Sophie E Vollenbrock; Jolanda M van Dieren; Francine E M Voncken; Sietze T van Turenhout; Liudmila L Kodach; Koen J Hartemink; Johanna W van Sandick; Berthe M P Aleman; Regina G H Beets-Tan; Annemarieke Bartels-Rutten
Journal:  Eur Radiol       Date:  2020-01-21       Impact factor: 5.315

9.  Induction chemoradiotherapy including docetaxel, cisplatin, and 5-fluorouracil for locally advanced esophageal cancer.

Authors:  Masashi Hashimoto; Yasuhiro Shirakawa; Naoaki Maeda; Shunsuke Tanabe; Kazuhiro Noma; Kazufumi Sakurama; Kuniaki Katsui; Masahiko Nishizaki; Toshiyoshi Fujiwara
Journal:  Esophagus       Date:  2020-01-02       Impact factor: 4.230

Review 10.  Towards an Organ-Sparing Approach for Locally Advanced Esophageal Cancer.

Authors:  Berend Jan van der Wilk; Ben M Eyck; Manon C W Spaander; Roelf Valkema; Sjoerd M Lagarde; Bas P L Wijnhoven; J Jan B van Lanschot
Journal:  Dig Surg       Date:  2018-09-18       Impact factor: 2.588

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.